The biotech has named Jamie Coleman its chief commercial officer, per a Monday announcement, putting her in charge of the ...
FDA formally announced the end of the tirzepatide shortage in a Declaratory Order issued to Eli Lilly & Co. (“Lilly”). Lilly ...
Lean mass constituted 30.8% of total body weight lost for adults who received a GLP-1 drug during a randomized controlled ...
Eli Lilly and Company ( NYSE:LLY – Get Free Report) last issued its quarterly earnings data on Wednesday, October 30th. The company reported $1.18 earnings per share (EPS) for the quarter, missing ...
The data appeared to slam the door on the idea that the advent of GLP-1 drugs would eliminate demand for drugs specifically ...
Bernstein analysts maintained their positive stance on Eli Lilly (NYSE:LLY) shares, reiterating an Outperform rating and a price target of $1,100.00. The endorsement comes amidst a competitive ...
Shares in Veru fell by nearly half following the news, despite positive results in preserving lean muscle mass.
Metsera has set its sights on a hefty $289 million IPO as the next-gen obesity biotech seeks to fund a phase 3 trial of its ...
Akero Therapeutics has hit a home run, reporting statistically significant results in two key 96-week metabolic ...
A Chinese start-up’s new artificial intelligence program took the top spot in Apple’s app store, threatening U.S. dominance ...
Failed to fetch dynamically imported module: https://uk.finance.yahoo.com/assets/_app/immutable/nodes/100.CtMQo59V.js ...